Dimensional Fund Advisors
SUPN icon

Dimensional Fund Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Dimensional Fund Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$119M Sell
2,307,030
-405,311
-15% -$20.6M 0.02% 949
2025
Q4 		$135M Sell
2,712,341
-289,600
-10% -$14.1M 0.03% 836
2025
Q3 		$143M Sell
3,001,941
-19,266
-0.6% -$776K 0.03% 792
2025
Q2 		$95.2M Buy
3,021,207
+117,480
+4% +$3.77M 0.02% 1051
2025
Q1 		$95.1M Buy
2,903,727
+25,182
+0.9% +$892K 0.02% 1015
2024
Q4 		$104M Sell
2,878,545
-3,960
-0.1% -$139K 0.03% 990
2024
Q3 		$89.9M Buy
2,882,505
+15,618
+0.5% +$487K 0.02% 1121
2024
Q2 		$76.7M Buy
2,866,887
+309,966
+12% +$8.98M 0.02% 1169
2024
Q1 		$87.2M Buy
2,556,921
+100,552
+4% +$2.99M 0.02% 1054
2023
Q4 		$71.1M Buy
2,456,369
+141,586
+6% +$3.75M 0.02% 1183
2023
Q3 		$63.8M Sell
2,314,783
-116,133
-5% -$3.54M 0.02% 1161
2023
Q2 		$73.1M Buy
2,430,916
+39,650
+2% +$1.39M 0.02% 1065
2023
Q1 		$86.6M Buy
2,391,266
+7,921
+0.3% +$305K 0.03% 923
2022
Q4 		$85K Buy
2,383,345
+112,865
+5% +$3.92M 0.03% 899
2022
Q3 		$76.9M Buy
2,270,480
+31,355
+1% +$1.02M 0.03% 887
2022
Q2 		$64.8M Buy
2,239,125
+17,805
+0.8% +$510K 0.02% 1066
2022
Q1 		$71.8M Sell
2,221,320
-19,301
-0.9% -$592K 0.02% 1112
2021
Q4 		$65.3M Sell
2,240,621
-34,430
-2% -$1.04M 0.02% 1219
2021
Q3 		$60.7M Sell
2,275,051
-1,134
-0% -$30.4K 0.02% 1246
2021
Q2 		$70.1M Buy
2,276,185
+144,093
+7% +$4.42M 0.02% 1148
2021
Q1 		$55.8M Buy
2,132,092
+197,229
+10% +$5.52M 0.02% 1352
2020
Q4 		$48.7M Sell
1,934,863
-29,972
-2% -$645K 0.02% 1396
2020
Q3 		$40.9M Buy
1,964,835
+4,824
+0.2% +$109K 0.02% 1362
2020
Q2 		$46.5M Buy
1,960,011
+143,121
+8% +$3.16M 0.02% 1259
2020
Q1 		$32.7M Buy
1,816,890
+154,883
+9% +$3.25M 0.02% 1407
2019
Q4 		$39.4M Buy
1,662,007
+59,297
+4% +$1.44M 0.01% 1640
2019
Q3 		$44M Buy
1,602,710
+162,379
+11% +$4.81M 0.02% 1502
2019
Q2 		$47.7M Buy
1,440,331
+61,765
+4% +$2.12M 0.02% 1469
2019
Q1 		$48.3M Buy
1,378,566
+64,805
+5% +$2.41M 0.02% 1453
2018
Q4 		$43.6M Sell
1,313,761
-21,130
-2% -$909K 0.02% 1402
2018
Q3 		$67.2M Sell
1,334,891
-15,093
-1% -$745K 0.03% 1112
2018
Q2 		$80.8M Sell
1,349,984
-54,010
-4% -$2.8M 0.03% 864
2018
Q1 		$64.3M Buy
1,403,994
+4,844
+0.3% +$202K 0.03% 1047
2017
Q4 		$55.8M Buy
1,399,150
+131,726
+10% +$5.21M 0.02% 1232
2017
Q3 		$50.7M Sell
1,267,424
-658
-0.1% -$28.5K 0.02% 1284
2017
Q2 		$54.7M Buy
1,268,082
+122,042
+11% +$4.34M 0.03% 1133
2017
Q1 		$35.9M Buy
1,146,040
+39,033
+4% +$1.05M 0.02% 1530
2016
Q4 		$28M Buy
1,107,007
+51,511
+5% +$1.15M 0.01% 1715
2016
Q3 		$26.1M Buy
1,055,496
+13,480
+1% +$305K 0.01% 1702
2016
Q2 		$21.2M Sell
1,042,016
-5,797
-0.6% -$103K 0.01% 1787
2016
Q1 		$16M Sell
1,047,813
-39,242
-4% -$512K 0.01% 1966
2015
Q4 		$14.6M Buy
1,087,055
+117,574
+12% +$1.82M 0.01% 2011
2015
Q3 		$13.6M Buy
969,481
+465,524
+92% +$8.66M 0.01% 2039
2015
Q2 		$8.56M Buy
+503,957
New +$7.17M 0.01% 2346

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors's SUPN Position: Q1 2026 in Review

Dimensional Fund Advisors reduced its Supernus Pharmaceuticals (SUPN) stake by 15% in Q1 2026, selling an estimated $20.6M and leaving 2,307,030 shares worth $119M. The position accounts for 0.02% of the portfolio, ranked #949.

Dimensional Fund Advisors first reported a position in SUPN in Q2 2015 and has held it in 44 quarters since. The position peaked at $143M in Q3 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Dimensional Fund Advisors held 2,307,030 shares of Supernus Pharmaceuticals worth $119M as of Q1 2026.
  • Dimensional Fund Advisors sold 405,311 Supernus Pharmaceuticals shares in Q1 2026, an estimated $20.6M.
  • Supernus Pharmaceuticals made up 0.02% of Dimensional Fund Advisors's portfolio in Q1 2026, its #949 holding.
  • Dimensional Fund Advisors first reported a position in Supernus Pharmaceuticals in Q2 2015 and has held it in 44 quarters since.
  • Dimensional Fund Advisors's Supernus Pharmaceuticals position peaked at $143M in Q3 2025.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.